Search

Your search keyword '"Castro Narro, Graciela E"' showing total 24 results
Start Over Author "Castro Narro, Graciela E"
24 results on '"Castro Narro, Graciela E"'

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F., Anstee, Quentin M., Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Castro Narro, Graciela E., Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, and Newsome, Philip N.

Published
2023
Full Text
View/download PDF

2. A global research priority agenda to advance public health responses to fatty liver disease

Author

Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Hagström, Hannes, Huang, Terry T-K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Miller, Veronica, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai-Sun, Younossi, Zobair M., Aberg, Fredrik, Adams, Leon, Al-Naamani, Khalid, Albadawy, Reda M., Alexa, Zinaida, Allison, Michael, Alnaser, Faisal A., Alswat, Khalid, Alvares-da-Silva, Mario Reis, Alvaro, Domenico, Alves-Bezerra, Michele, Andrade, Raul J., Anstee, Quentin M., Awuku, Yaw Asante, Baatarkhuu, Oidov, Baffy, Gyorgy, Bakieva, Shokhista, Bansal, Meena B., Barouki, Robert, Batterham, Rachel L., Behling, Cynthia, Belfort-DeAguiar, Renata, Berzigotti, Annalisa, Betel, Michael, Bianco, Cristiana, Bosi, Emanuele, Boursier, Jerome, Brunt, Elizabeth M., Bugianesi, Elisabetta, Byrne, Christopher J., Cabrera Cabrejos, Maria Cecilia, Caldwell, Stephen, Carr, Rotonya, Castellanos Fernández, Marlen Ivón, Castera, Laurent, Castillo-López, Maria Gabriela, Caussy, Cyrielle, Cerda-Reyes, Eira, Ceriello, Antonio, Chan, Wah- Kheong, Chang, Yoosoo, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chung, Raymond T., Colombo, Massimo, Coppell, Kirsten, Cotrim, Helma P., Craxi, Antonio, Crespo, Javier, Dassanayake, Anuradha, Davidson, Nicholas O., De Knegt, Robert, de Ledinghen, Victor, Demir, Münevver, Desalegn, Hailemichael, Diago, Moises, Dillon, John F., Dimmig, Bruce, Dirac, M. Ashworth, Dirchwolf, Melisa, Dufour, Jean-François, Dvorak, Karel, Ekstedt, Mattias, El-Kassas, Mohamed, Elsanousi, Osama M., Elsharkawy, Ahmed M., Elwakil, Reda, Eskridge, Wayne, Eslam, Mohammed, Esmat, Gamal, Fan, Jian- Gao, Ferraz, Maria Lucia, Flisiak, Robert, Fortin, Davide, Fouad, Yasser, Freidman, Scott L., Fuchs, Michael, Gadano, Adrian, Gastaldelli, Amalia, Geerts, Anja, Geier, Andreas, George, Jacob, Gerber, Lynn H., Ghazinyan, Hasmik, Gheorghe, Liana, Kile, Denise Giangola, Girala, Marcos, Boon Bee, George Goh, Goossens, Nicolas, Graupera, Isabel, Grønbæk, Henning, Hamid, Saeed, Hebditch, Vanessa, Henry, Zachary, Hickman, Ingrid J., Hobbs, L. Ansley, Hocking, Samantha L., Hofmann, Wolf Peter, Idilman, Ramazan, Iruzubieta, Paula, Isaacs, Scott, Isakov, Vasily A., Ismail, Mona H., Jamal, Mohammad H., Jarvis, Helen, Jepsen, Peter, Jornayvaz, François, Sudhamshu, K.C., Kakizaki, Satoru, Karpen, Saul, Kawaguchi, Takumi, Keating, Shelley E., Khader, Yousef, Kim, Seung Up, Kim, Won, Kleiner, David E., Koek, Ger, Joseph Komas, Narcisse Patrice, Kondili, Loreta A., Koot, Bart G., Korenjak, Marko, Kotsiliti, Eleni, Koulla, Yiannoula, Kugelmas, Carina, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Leite, Nathalie, Lin, Han-Chieh, Lkhagvaa, Undram, Long, Michelle T., Lopez-Jaramillo, Patricio, Lozano, Adelina, Macedo, Maria Paula, Malekzadeh, Reza, Marchesini, Giulio, Marciano, Sebastian, Martinez, Kim, Martínez Vázquez, Sophia E., Mateva, Lyudmila, Mato, José M., Nlombi, Charles Mbendi, McCary, Alexis Gorden, McIntyre, Jeff, McKee, Martin, Mendive, Juan M., Mikolasevic, Ivana, Miller, Pamela S., Milovanovic, Tamara, Milton, Terri, Moreno-Alcantar, Rosalba, Morgan, Timothy R., Motala, Ayesha, Muris, Jean, Musso, Carla, Nava-González, Edna J., Negro, Francesco, Nersesov, Alexander V., Neuschwander-Tetri, Brent A., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Ocama, Ponsiano, Ong, Janus P., Ong-Go, Arlinking, Onyekwere, Charles, Padilla, Martin, Pais, Raluca, Pan, Calvin, Panduro, Arturo, Panigrahi, Manas K., Papatheodoridis, Georgios, Paruk, Imran, Patel, Keyur, Gonçalves, Carlos Penha, Figueroa, Marlene Pérez, Pérez-Escobar, Juanita, Pericàs, Juan M., Perseghin, Gianluca, Pessoa, Mário Guimarães, Petta, Salvatore, Marques Souza de Oliveira, Claudia Pinto, Prabhakaran, Dorairaj, Pyrsopoulous, Nikolaos, Rabiee, Atoosa, Ramji, Alnoor, Ratziu, Vlad, Ravendhran, Natarajan, Ray, Katrina, Roden, Michael, Romeo, Stefano, Romero-Gómez, Manuel, Rotman, Yaron, Rouabhia, Samir, Rowe, Ian A., Sadirova, Shakhlo, Alkhatry, Maryam Salem, Salupere, Riina, Satapathy, Sanjaya K., Schwimmer, Jeffrey B., Sebastiani, Giada, Seim, Lynn, Seki, Yosuke, Serme, Abdel Karim, Shapiro, David, Sharvadze, Lali, Shaw, Jonathan E., Shawa, Isaac Thom, Shenoy, Thrivikrama, Shibolet, Oren, Shimakawa, Yusuke, Shubrook, Jay H., Singh, Shivaram Prasad, Sinkala, Edford, Skladany, Lubomir, Skrypnyk, Igor, Song, Myeong Jun, Sookoian, Silvia, Sridharan, Kannan, Stefan, Norbert, Stine, Jonathan G., Stratakis, Nikolaos, Sheriff, Dhastagir Sultan, Sundaram, Shikha S., Svegliati-Baroni, Gianluca, Swain, Mark G., Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Tapper, Elliot B., Targher, Giovanni, Tcaciuc, Eugen, Thiele, Maja, Tiniakos, Dina, Tolmane, Ieva, Torre, Aldo, Torres, Esther A., Treeprasertsuk, Sombat, Trenell, Michael, Turcan, Svetlana, Turcanu, Adela, Valantinas, Jonas, van Kleef, Laurens A., Velarde Ruiz Velasco, Jose Antonio, Vesterhus, Mette, Vilar-Gomez, Eduardo, Waked, Imam, Wattacheril, Julia, Wedemeyer, Heiner, Wilkins, Fonda, Willemse, José, Wong, Robert J., Yilmaz, Yusuf, Yki-Järvinen, Hannele, Yu, Ming-Lung, Yumuk, Volkan, Zeybel, Müjdat, Zheng, Kenneth I., Zheng, Ming-Hua, and Huang, Terry T.-K.

Published
2023
Full Text
View/download PDF

4. A global action agenda for turning the tide on fatty liver disease

Author

Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Anstee, Quentin M., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Gastaldelli, Amalia, Hagström, Hannes, Huang, Terry T.K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Terrault, Norah A., Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai Sun, Younossi, Zobair M., Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Anstee, Quentin M., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Gastaldelli, Amalia, Hagström, Hannes, Huang, Terry T.K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Terrault, Norah A., Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai Sun, and Younossi, Zobair M.

Abstract

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of "agree"responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% "agree"). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.

Published
2024

5. A global action agenda for turning the tide on fatty liver disease

Author

Lazarus, J, Mark, H, Allen, A, Arab, J, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, S, Anstee, Q, Arrese, M, Bataller, R, Berg, T, Brennan, P, Burra, P, Castro-Narro, G, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, S, Gastaldelli, A, Hagström, H, Huang, T, Ivancovsky Wajcman, D, Kautz, A, Kopka, C, Krag, A, Newsome, P, Rinella, M, Romero, D, Sarin, S, Silva, M, Spearman, C, Terrault, N, Tsochatzis, E, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, J, Wong, V, Younossi, Z, Perseghin, G, Lazarus, Jeffrey V, Mark, Henry E, Allen, Alina M, Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A, Anstee, Quentin M, Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N, Burra, Patrizia, Castro-Narro, Graciela E, Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M, Gastaldelli, Amalia, Hagström, Hannes, Huang, Terry T K, Ivancovsky Wajcman, Dana, Kautz, Achim, Kopka, Christopher J, Krag, Aleksander, Newsome, Philip N, Rinella, Mary E, Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C Wendy, Terrault, Norah A, Tsochatzis, Emmanuel A, Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M, Wong, Vincent Wai-Sun, Younossi, Zobair M, Perseghin, Gianluca, Lazarus, J, Mark, H, Allen, A, Arab, J, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, S, Anstee, Q, Arrese, M, Bataller, R, Berg, T, Brennan, P, Burra, P, Castro-Narro, G, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, S, Gastaldelli, A, Hagström, H, Huang, T, Ivancovsky Wajcman, D, Kautz, A, Kopka, C, Krag, A, Newsome, P, Rinella, M, Romero, D, Sarin, S, Silva, M, Spearman, C, Terrault, N, Tsochatzis, E, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, J, Wong, V, Younossi, Z, Perseghin, G, Lazarus, Jeffrey V, Mark, Henry E, Allen, Alina M, Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A, Anstee, Quentin M, Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N, Burra, Patrizia, Castro-Narro, Graciela E, Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M, Gastaldelli, Amalia, Hagström, Hannes, Huang, Terry T K, Ivancovsky Wajcman, Dana, Kautz, Achim, Kopka, Christopher J, Krag, Aleksander, Newsome, Philip N, Rinella, Mary E, Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C Wendy, Terrault, Norah A, Tsochatzis, Emmanuel A, Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M, Wong, Vincent Wai-Sun, Younossi, Zobair M, and Perseghin, Gianluca

Abstract

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.

Published
2024

6. Dislipidemia: recomendaciones para el diagnóstico y tratamiento en el primer nivel de contacto médico.

Author

Basurto, Maria de Lourdes, Abdo-Francis, Miguel, Aguilar-Salinas, Carlos A., Balcázar-Hernández, Lourdes J., Borrayo-Sánchez, Gabriela, Castro-Narro, Graciela E., Chávez-Negrete, Adolfo, Díaz-Aragón, Alejo, Enciso-Muñoz, José M., Fernández-Barros, Carlos, Ferreira-Hermosillo, Aldo, González-Chávez, Antonio, Guerra-López, Arturo, Gómez-Díaz, Rita, Molina-Ayala, Mario, Rodríguez-Gilabert, César, Tomás-López, Juan C., Vargas-Sánchez, Héctor R., and Ruiz-Gastelum, Edith

Abstract

Copyright of Gaceta Médica de México is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

9. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Author

Mary E, R, Jeffrey V, L, Vlad, R, Sven M, F, Arun J, S, Fasiha, K, Diana, R, Manal F, A, Quentin M, A, Juan Pablo, A, Marco, A, Ramon, B, Ulrich, B, Jerome, B, Elisabetta, B, Christopher, B, Graciela E, C, Abhijit, C, Helena, C, Donna, C, Kenneth, C, Mohamed, E, Samuel, K, Wayne, E, Jiangao, F, Samer, G, Cynthia D, G, Stephen A, H, Seung Up, K, Bart, K, Marko, K, Kris, K, Florence, L, Rohit, L, Robert, M, Timothy R, M, Elisabeth, P, Michael, R, Manuel, R, Marcelo, S, Shivaram Prasad, S, Silvia C, S, C Wendy, S, Dina, T, Luca, V, Miriam B, V, Vincent, W, Stavra, X, Yusuf, Y, Zobair, Y, Ansley, H, Marcela, V, Newsome, NVeeral Ajmeral, P, Alazawi, W, Alkhatry, M, Alkhouri, N, Allen, A, Allison, M, Alswat, K, R Alvares-da-Silva, M, Alves-Bezerra, M, J Armstrong, M, Arufe, D, Aschner, P, Baffy, G, Bansal, M, Bedossa, P, Belfort, R, Berg, T, Berzigotti, A, Betel, M, Bianco, C, Brass, C, L Brosgart, C, Matthews Brunt, E, Buti, M, Caldwell, S, Carr, R, Casanovas, T, Castera, L, Caussy, C, Cerda, E, Chalasani, N, Kheong Chan, W, Charatcharoenwitthaya, P, Charlton, M, Cheung, A, Chiodi, D, Chung, R, Cohen, D, Corey, K, P Cotrim, H, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, De Ledinghen, V, Demir, M, Diaz, S, Mae Diehl, A, Dimmig, B, Dirchwolf, M, Duseja, A, Dvorak, K, Ekstedt, M, El Wakil, R, Lucía Ferraz, M, Friedman, S, Fuchs, M, Gastaldelli, A, Geerts, A, Geier, A, Girala, M, Goh, G, Goossens, N, Graupera, I, Hagström, H, Henry, Z, Hunyady, B, Hutchison, A, Isaacs, S, Jornayvaz, F, Kemp, C, Kile, D, Kim, W, Kleiner, D, Kohli, R, Kugelmas, M, Lavine, J, Lazo, M, Leite, N, Lozano, A, Luukkonen, P, Macedo, P, Mansour, D, Mantzoros, C, Marchesini, G, Marciano, S, Martinez, K, Vladimirova Mateva, L, M Mato, J, Mccary, A, Miele, L, Mikolasevic, I, Miller, V, Moreno, R, Moylan, C, Nakajima, A, Charles Nault, J, Norris, S, Noureddin, M, P Oliveira, C, Ong, A, Padilla, M, Pais, R, Panduro, A, K Panigrahi, M, Papatheodoridis, G, Pelusi, S, Pérez, M, Perez Escobar, J, Perseghin, G, Pessoa, M, Petta, S, Pinzani, M, Platon Lupsor, M, Rabiee, A, Romeo, S, Rotman, Y, Rowe, I, Salupere, R, Satapathy, S, M Schattenberg, J, Schaufert, W, Schnabl, B, Seim, L, Serfaty, L, Shapiro, D, K Singal, A, Skladany, L, Stefan, N, Stine, J, Sundaram, S, Svegliati-Baroni, G, Szabo, G, Tacke, F, Tanwandee, T, Targher, G, Terrault, N, Tetri, B, Thiele, M, Tisthammer, B, Torre Delgadillo, A, Trauner, M, Tsochatzis, E, Van Kleef, L, Van Mil, S, Vanwagner, L, Antonio Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Watt, K, Wattacheril, J, Wilkins, F, Willemse, J, Zekry, A, Zelber-Sagi, S, Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Philip NVeeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart, Elizabeth Matthews Brunt, Maria Buti, Steve Caldwell, Rotonya Carr, Teresa Casanovas, Laurent Castera, Cyrielle Caussy, Eira Cerda, Naga Chalasani, Wah Kheong Chan, Phunchai Charatcharoenwitthaya, Michael Charlton, Amanda Cheung, Daniela Chiodi, Ray Chung, David Cohen, Kathleen Corey, Helma P Cotrim, Javier Crespo, Anuradha Dassanayake, Nicholas Davidson, Robert De Knegt, Victor De Ledinghen, Münevver Demir, Sebastian Diaz, Anna Mae Diehl, Bruce Dimmig, Melisa Dirchwolf, Ajay Duseja, Karel Dvorak, Mattias Ekstedt, Reda El Wakil, María Lucía Ferraz, Scott Friedman, Michael Fuchs, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Marcos Girala, George Goh, Nicolas Goossens, Isabel Graupera, Hannes Hagström, Zachary Henry, Bela Hunyady, Alan Hutchison, Scott Isaacs, François Jornayvaz, Cynthia Kemp, Denise Kile, Won Kim, David Kleiner, Rohit Kohli, Marcelo Kugelmas, Joel Lavine, Mariana Lazo, Nathalie Leite, Adelina Lozano, Panu Luukkonen, Paula Macedo, Dina Mansour, Christos Mantzoros, Giulio Marchesini, Sebastián Marciano, Kim Martinez, Lyudmila Vladimirova Mateva, Jose M Mato, Alexis McCary, Luca Miele, Ivana Mikolasevic, Veronica Miller, Rosalba Moreno, Cynthia Moylan, Atsushi Nakajima, Jean Charles Nault, Suzanne Norris, Mazen Noureddin, C P Oliveira, Arlin Ong, Martín Padilla, Raluca Pais, Arturo Panduro, Manas K Panigrahi, George Papatheodoridis, Serena Pelusi, Marlene Pérez, Juanita Perez Escobar, Gianluca Perseghin, Mario Pessoa, Salvatore Petta, Massimo Pinzani, Monica Platon Lupsor, Atoosa Rabiee, Stefano Romeo, Yaron Rotman, Ian Rowe, Riina Salupere, Sanjaya Satapathy, Jörn M Schattenberg, Wendy Schaufert, Bernd Schnabl, Lynn Seim, Lawrence Serfaty, David Shapiro, Ashwani K Singal, Lubomir Skladany, Norbert Stefan, Jonathan Stine, Shikha Sundaram, Gianluca Svegliati-Baroni, Gyonzgi Szabo, Frank Tacke, Tawesak Tanwandee, Giovanni Targher, Norah Terrault, Brent Tetri, Maja Thiele, Baron Tisthammer, Aldo Torre Delgadillo, Michael Trauner, Emmanuel Tsochatzis, Laurens Van Kleef, Saskia Van Mil, Lisa VanWagner, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Kymberly Watt, Julia Wattacheril, Fonda Wilkins, José Willemse, Amany Zekry, Shira Zelber-Sagi, Mary E, R, Jeffrey V, L, Vlad, R, Sven M, F, Arun J, S, Fasiha, K, Diana, R, Manal F, A, Quentin M, A, Juan Pablo, A, Marco, A, Ramon, B, Ulrich, B, Jerome, B, Elisabetta, B, Christopher, B, Graciela E, C, Abhijit, C, Helena, C, Donna, C, Kenneth, C, Mohamed, E, Samuel, K, Wayne, E, Jiangao, F, Samer, G, Cynthia D, G, Stephen A, H, Seung Up, K, Bart, K, Marko, K, Kris, K, Florence, L, Rohit, L, Robert, M, Timothy R, M, Elisabeth, P, Michael, R, Manuel, R, Marcelo, S, Shivaram Prasad, S, Silvia C, S, C Wendy, S, Dina, T, Luca, V, Miriam B, V, Vincent, W, Stavra, X, Yusuf, Y, Zobair, Y, Ansley, H, Marcela, V, Newsome, NVeeral Ajmeral, P, Alazawi, W, Alkhatry, M, Alkhouri, N, Allen, A, Allison, M, Alswat, K, R Alvares-da-Silva, M, Alves-Bezerra, M, J Armstrong, M, Arufe, D, Aschner, P, Baffy, G, Bansal, M, Bedossa, P, Belfort, R, Berg, T, Berzigotti, A, Betel, M, Bianco, C, Brass, C, L Brosgart, C, Matthews Brunt, E, Buti, M, Caldwell, S, Carr, R, Casanovas, T, Castera, L, Caussy, C, Cerda, E, Chalasani, N, Kheong Chan, W, Charatcharoenwitthaya, P, Charlton, M, Cheung, A, Chiodi, D, Chung, R, Cohen, D, Corey, K, P Cotrim, H, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, De Ledinghen, V, Demir, M, Diaz, S, Mae Diehl, A, Dimmig, B, Dirchwolf, M, Duseja, A, Dvorak, K, Ekstedt, M, El Wakil, R, Lucía Ferraz, M, Friedman, S, Fuchs, M, Gastaldelli, A, Geerts, A, Geier, A, Girala, M, Goh, G, Goossens, N, Graupera, I, Hagström, H, Henry, Z, Hunyady, B, Hutchison, A, Isaacs, S, Jornayvaz, F, Kemp, C, Kile, D, Kim, W, Kleiner, D, Kohli, R, Kugelmas, M, Lavine, J, Lazo, M, Leite, N, Lozano, A, Luukkonen, P, Macedo, P, Mansour, D, Mantzoros, C, Marchesini, G, Marciano, S, Martinez, K, Vladimirova Mateva, L, M Mato, J, Mccary, A, Miele, L, Mikolasevic, I, Miller, V, Moreno, R, Moylan, C, Nakajima, A, Charles Nault, J, Norris, S, Noureddin, M, P Oliveira, C, Ong, A, Padilla, M, Pais, R, Panduro, A, K Panigrahi, M, Papatheodoridis, G, Pelusi, S, Pérez, M, Perez Escobar, J, Perseghin, G, Pessoa, M, Petta, S, Pinzani, M, Platon Lupsor, M, Rabiee, A, Romeo, S, Rotman, Y, Rowe, I, Salupere, R, Satapathy, S, M Schattenberg, J, Schaufert, W, Schnabl, B, Seim, L, Serfaty, L, Shapiro, D, K Singal, A, Skladany, L, Stefan, N, Stine, J, Sundaram, S, Svegliati-Baroni, G, Szabo, G, Tacke, F, Tanwandee, T, Targher, G, Terrault, N, Tetri, B, Thiele, M, Tisthammer, B, Torre Delgadillo, A, Trauner, M, Tsochatzis, E, Van Kleef, L, Van Mil, S, Vanwagner, L, Antonio Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Watt, K, Wattacheril, J, Wilkins, F, Willemse, J, Zekry, A, Zelber-Sagi, S, Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Philip NVeeral Ajmeral, William Alazawi, Maryam Alkhatry, Naim Alkhouri, Alina Allen, Michael Allison, Khalid Alswat, Mario R Alvares-da-Silva, Michele Alves-Bezerra, Matthew J Armstrong, Diego Arufe, Pablo Aschner, Gyorgy Baffy, Meena Bansal, Pierre Bedossa, Renata Belfort, Thomas Berg, Annalisa Berzigotti, Michael Betel, Cristiana Bianco, Clifford Brass, Carol L Brosgart, Elizabeth Matthews Brunt, Maria Buti, Steve Caldwell, Rotonya Carr, Teresa Casanovas, Laurent Castera, Cyrielle Caussy, Eira Cerda, Naga Chalasani, Wah Kheong Chan, Phunchai Charatcharoenwitthaya, Michael Charlton, Amanda Cheung, Daniela Chiodi, Ray Chung, David Cohen, Kathleen Corey, Helma P Cotrim, Javier Crespo, Anuradha Dassanayake, Nicholas Davidson, Robert De Knegt, Victor De Ledinghen, Münevver Demir, Sebastian Diaz, Anna Mae Diehl, Bruce Dimmig, Melisa Dirchwolf, Ajay Duseja, Karel Dvorak, Mattias Ekstedt, Reda El Wakil, María Lucía Ferraz, Scott Friedman, Michael Fuchs, Amalia Gastaldelli, Anja Geerts, Andreas Geier, Marcos Girala, George Goh, Nicolas Goossens, Isabel Graupera, Hannes Hagström, Zachary Henry, Bela Hunyady, Alan Hutchison, Scott Isaacs, François Jornayvaz, Cynthia Kemp, Denise Kile, Won Kim, David Kleiner, Rohit Kohli, Marcelo Kugelmas, Joel Lavine, Mariana Lazo, Nathalie Leite, Adelina Lozano, Panu Luukkonen, Paula Macedo, Dina Mansour, Christos Mantzoros, Giulio Marchesini, Sebastián Marciano, Kim Martinez, Lyudmila Vladimirova Mateva, Jose M Mato, Alexis McCary, Luca Miele, Ivana Mikolasevic, Veronica Miller, Rosalba Moreno, Cynthia Moylan, Atsushi Nakajima, Jean Charles Nault, Suzanne Norris, Mazen Noureddin, C P Oliveira, Arlin Ong, Martín Padilla, Raluca Pais, Arturo Panduro, Manas K Panigrahi, George Papatheodoridis, Serena Pelusi, Marlene Pérez, Juanita Perez Escobar, Gianluca Perseghin, Mario Pessoa, Salvatore Petta, Massimo Pinzani, Monica Platon Lupsor, Atoosa Rabiee, Stefano Romeo, Yaron Rotman, Ian Rowe, Riina Salupere, Sanjaya Satapathy, Jörn M Schattenberg, Wendy Schaufert, Bernd Schnabl, Lynn Seim, Lawrence Serfaty, David Shapiro, Ashwani K Singal, Lubomir Skladany, Norbert Stefan, Jonathan Stine, Shikha Sundaram, Gianluca Svegliati-Baroni, Gyonzgi Szabo, Frank Tacke, Tawesak Tanwandee, Giovanni Targher, Norah Terrault, Brent Tetri, Maja Thiele, Baron Tisthammer, Aldo Torre Delgadillo, Michael Trauner, Emmanuel Tsochatzis, Laurens Van Kleef, Saskia Van Mil, Lisa VanWagner, Jose Antonio Velarde Ruiz Velasco, Mette Vesterhus, Eduardo Vilar-Gomez, Kymberly Watt, Julia Wattacheril, Fonda Wilkins, José Willemse, Amany Zekry, and Shira Zelber-Sagi

Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmati

Published
2023

10. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kri, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, Miele, Luca, NAFLD Nomenclature consensus, Group, Miele, Luca (ORCID:0000-0003-3464-0068), Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela E, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart, Korenjak, Marko, Kowdley, Kri, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wai-Sun Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, Miele, Luca, NAFLD Nomenclature consensus, Group, and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

Unlabelled: The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. Methods: A modified Delphi process was led by three large pan-national liver associations. Consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. Results: A total of 236 panellists from 56 countries participated in four online surveys and two hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83% and 78%, respectively. 74% of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms 'non-alcoholic' and 'fatty' were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease (SLD) was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least one of five cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic SLD. A new category, outside pure MASLD, termed MetALD was selected to describe those with MASLD who consume greater amounts of alcohol per week (140 to 350 g/week and 210 to 420 g/week for females and males respectively). Conclusions: The new nomenclature and diagnostic criteria are widely supported, non-stigmatising and can improve awareness and patient identification.

Published
2023

11. Research Priorities for Precision Medicine in NAFLD

Author

Iruzubieta, Paula, Bataller, Ramón, Arias-Loste, María Teresa, Arrese, Marco, Calleja, José Luis, Castro Narro, Graciela E., Cusi, Kenneth, Dillon, John F., Martínez-Chantar, María Luz, Mateo, Miguel, Pérez, Antonio, Rinella, Mary E., Romero-Gómez, Manuel, Schattenberg, Jörn M., Zelber-Sagi, Shira, Crespo, Javier, Lazarus, Jeffrey V., Iruzubieta, Paula, Bataller, Ramón, Arias-Loste, María Teresa, Arrese, Marco, Calleja, José Luis, Castro Narro, Graciela E., Cusi, Kenneth, Dillon, John F., Martínez-Chantar, María Luz, Mateo, Miguel, Pérez, Antonio, Rinella, Mary E., Romero-Gómez, Manuel, Schattenberg, Jörn M., Zelber-Sagi, Shira, Crespo, Javier, and Lazarus, Jeffrey V.

Published
2023

12. OP-4 IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH CHRONIC HEPATITIS C WHO WERE LOST TO FOLLOW-UP IN LATIN AMERICA

Author

Mendizabal, Manuel, primary, Thompson, Marcos, additional, Gonzalez-Ballerga, Esteban, additional, Anders, Margarita, additional, Castro-Narro, Graciela E, additional, Pessoa, Mario G, additional, Cheinquer, Hugo, additional, Mezzano, Gabriel, additional, Palazzo, Ana, additional, Ridruejo, Ezequiel, additional, Descalzi, Valeria, additional, Velasco, Jose A Velarde-Ruiz, additional, Marciano, Sebastian, additional, Muñoz, Linda, additional, Schinoni, Maria I, additional, Poniachik, Jaime, additional, Perazzo, Rosalía, additional, Cerda, Eira, additional, Fuster, Francisco, additional, Varon, Adriana, additional, García, Sandro Ruiz, additional, Soza, Alejandro, additional, Cabrera, Cecilia, additional, Gomez-Aldana, Andres J, additional, Beltrán, Flor de María, additional, Gerona, Solange, additional, Cocozzella, Daniel, additional, Bessone, Fernando, additional, Hernández, Nelia, additional, Alonso, Cristina, additional, Ferreiro, Melina, additional, Antinucci, Florencia, additional, Torre, Aldo, additional, Moutinho, Bruna D, additional, Borges, Silvia Coelho, additional, Gomez, Fernando, additional, Murga, Maria Dolores, additional, Piñero, Federico, additional, Sotera, Gisela F, additional, Ocampo, Jhonier A, additional, Mollinedo, Valeria A Cortés, additional, Girala, Marcos, additional, Montes, Pedro, additional, Ratusnu, Natalia, additional, Zuñagua, Claudia A, additional, Castillo, Lida, additional, Barradas, Mauricio Castillo, additional, Chávez, Rocío, additional, Ivantes, Cláudia, additional, Brutti, Julia, additional, Tenorio, Laura, additional, Garavito, Jorge, additional, Zevallos, Katherine, additional, Contreras, Fernando, additional, Infante, Mirtha, additional, Vera-Pozo, Emilia, additional, Tagle, Martín, additional, Toro, Luis G, additional, Rocha, Carlos A De La, additional, Simian, Daniela, additional, and Silva, Marcelo O, additional

Published
2023
Full Text
View/download PDF

13. A global research priority agenda to advance public health responses to fatty liver disease

Author

Lazarus, Jeffrey V, Mark, Henry E, Allen, Alina M, Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A, Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N, Burra, Patrizia, Castro-Narro, Graciela E, Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M, Hagström, Hannes, Huang, Terry T-K, Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J, Krag, Aleksander, Miller, Veronica, Newsome, Philip N, Rinella, Mary E, Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C Wendy, Tsochatzis, Emmanuel A, Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M, Wong, Vincent Wai-Sun, Younossi, Zobair M, Gianluca Perseghin, Jeffrey V, L, Henry E, M, Alina M, A, Juan Pablo, A, Patrizia, C, Mazen, N, William, A, Naim, A, Saleh A, A, Marco, A, Ramon, B, Thomas, B, Paul N, B, Patrizia, B, Graciela E, C, Helena, C, Kenneth, C, Nikos, D, Ajay, D, Sven M, F, Hannes, H, Terry T-K, H, Dana Ivancovsky, W, Achim, K, Christopher J, K, Aleksander, K, Veronica, M, Philip N, N, Mary E, R, Diana, R, Shiv Kumar, S, Marcelo, S, C Wendy, S, Emmanuel A, T, Luca, V, Marcela, V, Shira, Z, Jörn M, S, Vincent Wai-Sun, W, Younossi, M, Z, and Perseghin, G

Subjects
Non-communicable disease (NCD), Steatotic liver disease, Delphi method, Global health, NAFLD/NASH
Abstract

Background & aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had 90% combined agreement. Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications: An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.

Published
2023

14. Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America

Author

Mendizabal, Manuel, primary, Thompson, Marcos, additional, Gonzalez‐Ballerga, Esteban, additional, Anders, Margarita, additional, Castro‐Narro, Graciela E., additional, Pessoa, Mario G., additional, Cheinquer, Hugo, additional, Mezzano, Gabriel, additional, Palazzo, Ana, additional, Ridruejo, Ezequiel, additional, Descalzi, Valeria, additional, Velarde‐Ruiz Velasco, Jose A., additional, Marciano, Sebastian, additional, Muñoz, Linda, additional, Schinoni, Maria I., additional, Poniachik, Jaime, additional, Perazzo, Rosalía, additional, Cerda, Eira, additional, Fuster, Francisco, additional, Varon, Adriana, additional, Ruiz García, Sandro, additional, Soza, Alejandro, additional, Cabrera, Cecilia, additional, Gomez‐Aldana, Andres J., additional, Beltrán, Flor de María, additional, Gerona, Solange, additional, Cocozzella, Daniel, additional, Bessone, Fernando, additional, Hernández, Nelia, additional, Alonso, Cristina, additional, Ferreiro, Melina, additional, Antinucci, Florencia, additional, Torre, Aldo, additional, Moutinho, Bruna D., additional, Coelho Borges, Silvia, additional, Gomez, Fernando, additional, Murga, Maria Dolores, additional, Piñero, Federico, additional, Sotera, Gisela F., additional, Ocampo, Jhonier A., additional, Cortés Mollinedo, Valeria A., additional, Simian, Daniela, additional, and Silva, Marcelo O., additional

Published
2022
Full Text
View/download PDF

16. Implementation of a re‐linkage to care strategy in patients with chronic hepatitis C who were lost to follow‐up in Latin America.

Author

Mendizabal, Manuel, Thompson, Marcos, Gonzalez‐Ballerga, Esteban, Anders, Margarita, Castro‐Narro, Graciela E., Pessoa, Mario G., Cheinquer, Hugo, Mezzano, Gabriel, Palazzo, Ana, Ridruejo, Ezequiel, Descalzi, Valeria, Velarde‐Ruiz Velasco, Jose A., Marciano, Sebastian, Muñoz, Linda, Schinoni, Maria I., Poniachik, Jaime, Perazzo, Rosalía, Cerda, Eira, Fuster, Francisco, and Varon, Adriana

Subjects
CHRONIC hepatitis C, HEPATITIS C virus, NOSOLOGY
Abstract

To achieve WHO's goal of eliminating hepatitis C virus (HCV), innovative strategies must be designed to diagnose and treat more patients. Therefore, we aimed to describe an implementation strategy to identify patients with HCV who were lost to follow‐up (LTFU) and offer them re‐linkage to HCV care. We conducted an implementation study utilizing a strategy to contact patients with HCV who were not under regular follow‐up in 13 countries from Latin America. Patients with HCV were identified by the international classification of diseases (ICD‐9/10) or equivalent. Medical records were then reviewed to confirm the diagnosis of chronic HCV infection defined by anti‐HCV+ and detectable HCV‐RNA. Identified patients who were not under follow‐up by a liver specialist were contacted by telephone or email, and offered a medical reevaluation. A total of 10,364 patients were classified to have HCV. After reviewing their medical charts, 1349 (13%) had undetectable HCV‐RNA or were wrongly coded. Overall, 9015 (86.9%) individuals were identified with chronic HCV infection. A total of 5096 (56.5%) patients were under routine HCV care and 3919 (43.5%) had been LTFU. We were able to contact 1617 (41.3%) of the 3919 patients who were LTFU at the primary medical institution, of which 427 (26.4%) were cured at a different institutions or were dead. Of the remaining patients, 906 (76.1%) were candidates for retrieval. In our cohort, about one out of four patients with chronic HCV who were LTFU were candidates to receive treatment. This strategy has the potential to be effective, accessible and significantly impacts on the HCV care cascade. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’.

Author

Rinella, Mary E., Castro Narro, Graciela E., Krag, Aleksander, Terrault, Norah, and Newsome, Philip N.

Subjects
NON-alcoholic fatty liver disease, MEDICAL personnel, DISEASE risk factors, SECONDARY prevention, NON-communicable diseases
Abstract

This document is a reply to a letter discussing the new definition of metabolic-associated fatty liver disease (MASLD). The authors of the reply defend the requirement of a cardiometabolic risk factor (CMRF) for the diagnosis of MASLD, stating that it is important for understanding the comorbidities associated with hepatic steatosis and for predicting outcomes. They argue that insulin resistance, while significant, may not be evident in routine testing and that other cardiometabolic risk factors should be considered. The authors also emphasize that MASLD overlaps almost entirely with non-alcoholic fatty liver disease (NAFLD) and that the new definition was designed to accommodate prior literature on NAFLD. The article discusses the proposed new nomenclature for steatotic liver disease (SLD) and its implications for clinical care and research. The authors argue that the new term, "metabolic dysfunction-associated steatotic liver disease" (MASLD), is clinically irrelevant and overlooks other potential causes of steatosis. They support maintaining the current alcohol thresholds for defining MASLD and emphasize the importance of cardiometabolic risk factors in disease incidence and progression. The authors also highlight the need for further research and validation in different contexts. They suggest that biomarkers and scores can be valuable tools for identifying hepatic steatosis, particularly in low- and middle-income countries where imaging may be less accessible. They emphasize the importance of multi-disciplinary collaboration and public health efforts in managing SLD and raising awareness among [Extracted from the article]

Published
2024
Full Text
View/download PDF

18. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, Jeffrey V., Mark, Henry E., Anstee, Quentin M., Arab, Juan Pablo, Batterham, Rachel L., Castera, Laurent, Cortez-Pinto, Helena, Crespo, Javier, Cusi, Kenneth, Dirac, M. Ashworth, Francque, Sven, Hickman, Ingrid J., Hocking, Samantha L., Hunyady, Bela, Idilman, Ramazan, Isakov, Vasily A., Jamal, Mohammad H., Jepsen, Peter, Iskandar, Natacha Jreige, Song, Myeong Jun, Sudhamshu, K. C., George, Jacob, Kakizaki, Satoru, Kalamitsis, George, Kanwal, Fasiha, Kao, Jia-Horng, Kaplan, Lee, Kawaguchi, Takumi, Khader, Yousef, Kim, Seung Up, Kodjoh, Nicolas, Koek, Ger, Hagström, Hannes, Koike, Kazuhiko, Komas, Narcisse Patrice, Korenjak, Marko, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Lee, Nancy, Lesmana, Cosmas Rinaldi A., Huang, Terry T.-K., Liu, Chun-Jen, Long, Michelle T., Lopez-Jaramillo, Patricio, Malekzadeh, Reza, Mahtab, Mamun Al, Marchesini, Giulio, Marinho, Rui, Vázquez, Sophia E. Martínez, Mateva, Lyudmila, Nlombi, Charles Mbendi, Ismail, Mona H., Melin, Pascal, Mikolasevic, Ivana, Milovanovic, Tamara, Musso, Carla, Nakajima, Atsushi, Nava, Edna, Nersesov, Alexander V., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Kautz, Achim, Oben, Jude, Ong, Janus P., Onyekwere, Charles, Papatheodoridis, George, Paruk, Imran, Patel, Keyur, Macedo, M. Paula, Penha-Gonçalves, Carlos, Figueroa, Marlene Pérez, Hofmann, Wolf Peter, Sarin, Shiv Kumar, Petta, Salvatore, de Oliveira, Claudia Pinto Marques Souza, Puri, Puneet, Pan, Calvin Q., Rac, Marek, Ralston, Johanna, Ramji, Alnoor, Razavi, Homie, Alvares-da-Silva, Mario Reis, Roberts, Stuart, Loomba, Rohit, Roden, Michael, Rose, Tamsin, Rouabhia, Samir, Rovere-Querini, Patrizia, Rowe, Ian A., Sadirova, Shakhlo, Salupere, Riina, Saparbu, Tobokalova, Sayegh, Raymond, Sebastiani, Giada, Miller, Veronica, Seki, Yosuke, Selmo, Josefina, Serme, Abdel Karim, Shaw, Jonathan E., Shenoy, Thrivikrama, Sheron, Nick, Shibolet, Oren, Silva, Marcelo, Skrypnyk, Igor, Socha, Piotr, Newsome, Philip N., Soriano, Joan, Spearman, C. Wendy, Sridharan, Kannan, Suárez, Juan José, Sheriff, Dhastagir Sultan, Sung, Ki-Chul, Swain, Mark, Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Ninburg, Michael, Tapper, Elliot B., Yki-Järvinen, Hannele, Thiele, Maja, Shawa, Isaac Thom, Tolmane, Ieva, Torres, Esther A., Trauner, Michael, Treeprasertsuk, Sombat, Turcanu, Adela, Valantinas, Jonas, Ocama, Ponsiano, Vesterhus, Mette, Waked, Imam, Wild, Sarah H., Willemse, Jose, Wong, Robert J., Xanthakos, Stavra, Young, Dan Yock, Yu, Ming-Lung, Zheng, Kenneth I., Zeybel, Mudjat, Ratziu, Vlad, Zheng, Ming-Hua, Rinella, Mary, Romero, Diana, Romero-Gómez, Manuel, Schattenberg, Jörn M., Tsochatzis, Emmanuel A., Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M., Zelber-Sagi, Shira, Åberg, Fredrik, Adams, Leon, Khatry, Maryam Salem Al, Naamani, Khalid Al, Murillo, Omar Alfaro, Allen, Alina M., Alnaser, Faisal, Alqahtani, Saleh A., Alswat, Khalid, Alvaro, Domenico, Andrade, Raúl J., Arrese, Marco, Awuku, Yaw Asante, Ayesha, Motala, Baatarkhuu, Oidov, Bakieva, Shokhista, Basu, Rita, Bataller, Ramon, Bedri, Shahinaz, Bosi, Emanuele, Bourliere, Marc, Bruha, Radan, Bugianesi, Elisabetta, Burra, Patrizia, Buti, Maria, Byrne, Christopher D., Calleja, Jose Luis, Carrieri, Patrizia, Carter, Flloyd, Fernandez, Marlen Ivon Castellanos, Castillo-Lopez, Gabriela, Castro-Narro, Graciela E., Chan, Henry Lik Yuen, Chan, Wah-Kheong, Chang, Yoosoo, Colombo, Massimo, Coppell, Kirsten J., Corey, Kathleen, Craxi, Antonio, Cryer, Donna, Dassanayake, Anuradha, Martins, Antonieta de Ascenção Soares, de Ledinghen, Victor, DelPrato, Stefano, Demaio, Alessandro, Desalegn, Hailemichael, Dillon, John, Duseja, Ajay, Dorairaj, Prabhakaran, Ekstedt, Mattias, El Kassas, Mohamed, Elsanousi, Osama M., Esmat, Gamal, Fan, Jian-Gao, Farpour-Lambert, Nathalie, Flisiak, Robert, Fouad, Yasser, Fuchs, Michael, Gani, Rino A., Gerber, Lynn, Ghazinyan, Hasmik, Gheorghe, Liana, Goh, George Boon-Bee, Grønbæk, Henning, Gulnara, Aghayeva, Hamid, Saeed, Hebditch, Vanessa, Repositório da Universidade de Lisboa, Masira, Lazarus, Jeffrey, V, Mark, Henry E., Anstee, Quentin M., Arab, Juan Pablo, Batterham, Rachel L., Castera, Laurent, Cortez-Pinto, Helena, Crespo, Javier, Cusi, Kenneth, Dirac, M. Ashworth, Francque, Sven, George, Jacob, Hagstrom, Hannes, Huang, Terry T-K, Ismail, Mona H., Kautz, Achim, Sarin, Shiv Kumar, Loomba, Rohit, Miller, Veronica, Newsome, Philip N., Ninburg, Michael, Ocama, Ponsiano, Ratziu, Vlad, Rinella, Mary, Romero, Diana, Romero-Gomez, Manuel, Schattenberg, Jorn M., Tsochatzis, Emmanuel A., Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M., Zelber-Sagi, Shira, Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagstrom, H., Huang, T. T. -K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gomez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W. -S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., Aberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W. -K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. A. S., de Ledinghen, V., Delprato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J. -G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B. -B., Gronbaek, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J. -H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C. -J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vazquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Goncalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suarez, J. J., Sheriff, D. S., Sung, K. -C., Swain, M., Tacke, F., Taheri, S., Tan, S. -S., Tapper, E. B., Yki-Jarvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M. -L., Zheng, K. I., Zeybel, M., Zheng, M. -H., NAFLD Consensus Consortium, Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M.A., Francque S., George J., Hagstrom H., Huang T.T.-K., Ismail M.H., Kautz A., Sarin S.K., Loomba R., Miller V., Newsome P.N., Ninburg M., Ocama P., Ratziu V., Rinella M., Romero D., Romero-Gomez M., Schattenberg J.M., Tsochatzis E.A., Valenti L., Wong V.W.-S., Yilmaz Y., Younossi Z.M., Zelber-Sagi S., Aberg F., Adams L., Khatry M.S.A., Naamani K.A., Murillo O.A., Allen A.M., Alnaser F., Alqahtani S.A., Alswat K., Alvaro D., Andrade R.J., Arrese M., Awuku Y.A., Ayesha M., Baatarkhuu O., Bakieva S., Basu R., Bataller R., Bedri S., Bosi E., Bourliere M., Bruha R., Bugianesi E., Burra P., Buti M., Byrne C.D., Calleja J.L., Carrieri P., Carter F., Fernandez M.I.C., Castillo-Lopez G., Castro-Narro G.E., Chan H.L.Y., Chan W.-K., Chang Y., Colombo M., Coppell K.J., Corey K., Craxi A., Cryer D., Dassanayake A., Martins A.A.S., de Ledinghen V., DelPrato S., Demaio A., Desalegn H., Dillon J., Duseja A., Dorairaj P., Ekstedt M., El Kassas M., Elsanousi O.M., Esmat G., Fan J.-G., Farpour-Lambert N., Flisiak R., Fouad Y., Fuchs M., Gani R.A., Gerber L., Ghazinyan H., Gheorghe L., Goh G.B.-B., Gronbaek H., Gulnara A., Hamid S., Hebditch V., Hickman I.J., Hocking S.L., Hunyady B., Idilman R., Isakov V.A., Jamal M.H., Jepsen P., Iskandar N.J., Song M.J., Sudhamshu K.C., Kakizaki S., Kalamitsis G., Kanwal F., Kao J.-H., Kaplan L., Kawaguchi T., Khader Y., Kim S.U., Kodjoh N., Koek G., Koike K., Komas N.P., Korenjak M., Kugelmas M., Labidi A., Lange N.F., Lavine J.E., Lazo M., Lee N., Lesmana C.R.A., Liu C.-J., Long M.T., Lopez-Jaramillo P., Malekzadeh R., Mahtab M.A., Marchesini G., Marinho R., Vazquez S.E.M., Mateva L., Nlombi C.M., Melin P., Mikolasevic I., Milovanovic T., Musso C., Nakajima A., Nava E., Nersesov A.V., Nikolova D., Norris S., Novak K., Oben J., Ong J.P., Onyekwere C., Papatheodoridis G., Paruk I., Patel K., Macedo M.P., Penha-Goncalves C., Figueroa M.P., Hofmann W.P., Petta S., de Oliveira C.P.M.S., Puri P., Pan C.Q., Rac M., Ralston J., Ramji A., Razavi H., Alvares-da-Silva M.R., Roberts S., Roden M., Rose T., Rouabhia S., Rovere-Querini P., Rowe I.A., Sadirova S., Salupere R., Saparbu T., Sayegh R., Sebastiani G., Seki Y., Selmo J., Serme A.K., Shaw J.E., Shenoy T., Sheron N., Shibolet O., Silva M., Skrypnyk I., Socha P., Soriano J., Spearman C.W., Sridharan K., Suarez J.J., Sheriff D.S., Sung K.-C., Swain M., Tacke F., Taheri S., Tan S.-S., Tapper E.B., Yki-Jarvinen H., Thiele M., Shawa I.T., Tolmane I., Torres E.A., Trauner M., Treeprasertsuk S., Turcanu A., Valantinas J., Vesterhus M., Waked I., Wild S.H., Willemse J., Wong R.J., Xanthakos S., Young D.Y., Yu M.-L., Zheng K.I., Zeybel M., and Zheng M.-H.

Subjects
medicine.medical_specialty, Civil society, Delphi method, MEDLINE, Nash, MULTIDISCIPLINARY APPROACH, Disease, LATIN-AMERICAN ASSOCIATION, Multidisciplinary approach, QUALITY-OF-LIFE, Non-alcoholic Fatty Liver Disease, Epidemiology, Medicine, Humans, POSITION STATEMENT, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, FATTY LIVER-DISEASE, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Hepatology, business.industry, Public health, Gastroenterology, ALCOHOLIC STEATOHEPATITIS, NONINVASIVE DIAGNOSIS, medicine.disease, Obesity, CARDIOVASCULAR-DISEASE, PRACTICE GUIDELINES, Family medicine, PRACTICAL APPROACH, Human medicine, business
Abstract

Digital, Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD., Ciencias Médicas y de la Salud

Published
2021
Full Text
View/download PDF

19. Uso de la endoscopia por síntomas de reflujo gastroesofágico en una muestra de población adulta mexicana

Author

Contreras-Omaña, Raúl, primary, Silva-de la Vega, Isis, additional, Velarde-Ruíz Velasco, José A., additional, Madrigal-Sánchez, Diana, additional, Higuera-de la Tijera, Ma. Fatima, additional, Zamarripa-Dorsey, Felipe, additional, Castro-Narro, Graciela E., additional, Téllez-Jaén, Stephany, additional, and Martínez-Campos, Juan F., additional

Published
2021
Full Text
View/download PDF

22. A global action agenda for turning the tide on fatty liver disease.

Author

Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, and Younossi ZM

Subjects
Humans, Delivery of Health Care, Liver Diseases
Abstract

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care., Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of "agree" responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% "agree"). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance., Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

23. Dyslipidemia: recommendations for diagnosis and treatment at the first level of medical contact.

Author

Basurto ML, Abdo-Francis M, Aguilar-Salinas CA, Balcázar-Hernández LJ, Borrayo-Sánchez G, Castro-Narro GE, Chávez-Negrete A, Díaz-Aragón A, Enciso-Muñoz JM, Fernández-Barros C, Ferreira-Hermosillo A, González-Chávez A, Guerra-López A, Gómez-Díaz R, Molina-Ayala M, Rodríguez-Gilabert C, Ruiz-Gastelum E, Tomás-López JC, Vargas-Sánchez HR, and Ruiz-Gastelum E

Subjects
Humans, Mexico, Delphi Technique, Secondary Prevention methods, Primary Health Care, Primary Prevention, Risk Factors, Young Adult, Lipids blood, Dyslipidemias diagnosis, Dyslipidemias therapy, Cardiovascular Diseases prevention & control, Cardiovascular Diseases diagnosis, Cardiovascular Diseases etiology
Abstract

Cardiovascular disease is the main cause of mortality in Mexico as well as the rest of the world, with dyslipidemia being one of the main risk factors. Despite the importance of its epidemiological impact, there is still -among primary care physicians- a lack of knowledge ranging from the basic concepts for diagnosis to the most recent recommendations for treatment. This document consisting of 10 questions is done by experts in this field. A total of 22 recommendations arise using Delphi methodology. The recommendations include the measurement of the lipid profile starting at 20 years of age, the treatment goals for patients according to their risk, the follow-up of patients with dyslipidemia, and the management approach in primary and secondary prevention., (Copyright: © 2024 Permanyer.)

Published
2024
Full Text
View/download PDF

24. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Author

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, and Newsome PN

Subjects
Male, Female, Humans, Delphi Technique, Hepatomegaly, Surveys and Questionnaires, Non-alcoholic Fatty Liver Disease diagnosis, Non-alcoholic Fatty Liver Disease metabolism
Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification., (Copyright © 2023 American Association for the Study of Liver Disease, European Association for the Study of the Liver (EASL), and Fundación Clínica Médica Sur, A.C. Published by Wolters Kluwer/Elsevier B.V/Elsevier España, S.L.U.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results